Trial Profile

Prospective, Phase II , non-randomised interventional case series of the safety and efficacy of the use of intra-vitreal bevacizumab ("Avastin") in the treatment of macular oedema secondary to diabetic retinopathy and uveitis, and for choroidal neovascular membranes secondary to uveitis, with respect to visual acuity and central macular thickness

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema
Focus Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com